CA3204051A1 - Compositions and methods for the treatment of metabolic and liver disorders - Google Patents

Compositions and methods for the treatment of metabolic and liver disorders

Info

Publication number
CA3204051A1
CA3204051A1 CA3204051A CA3204051A CA3204051A1 CA 3204051 A1 CA3204051 A1 CA 3204051A1 CA 3204051 A CA3204051 A CA 3204051A CA 3204051 A CA3204051 A CA 3204051A CA 3204051 A1 CA3204051 A1 CA 3204051A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
hydrogen
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204051A
Other languages
English (en)
French (fr)
Inventor
Brian Lian
Geoffrey E. Barker
Kader YAGIZ
Maureen BARNES
Erland STEVENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viking Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3204051A1 publication Critical patent/CA3204051A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3204051A 2021-01-20 2022-01-18 Compositions and methods for the treatment of metabolic and liver disorders Pending CA3204051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163139676P 2021-01-20 2021-01-20
US63/139,676 2021-01-20
PCT/US2022/012807 WO2022159395A1 (en) 2021-01-20 2022-01-18 Compositions and methods for the treatment of metabolic and liver disorders

Publications (1)

Publication Number Publication Date
CA3204051A1 true CA3204051A1 (en) 2022-07-28

Family

ID=82549660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204051A Pending CA3204051A1 (en) 2021-01-20 2022-01-18 Compositions and methods for the treatment of metabolic and liver disorders

Country Status (10)

Country Link
US (2) US11744873B2 (zh)
EP (1) EP4281464A1 (zh)
JP (1) JP2023554693A (zh)
KR (1) KR20230125093A (zh)
CN (1) CN116710462A (zh)
AU (1) AU2022210988B9 (zh)
CA (1) CA3204051A1 (zh)
IL (1) IL304214A (zh)
MX (1) MX2023008330A (zh)
WO (1) WO2022159395A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023141044A1 (en) * 2022-01-18 2023-07-27 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
JP2013510829A (ja) 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
EP2542565A1 (en) 2010-03-01 2013-01-09 Novo Nordisk A/S Preparative rp-hplc method for purifying peptides
US20130143798A1 (en) 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
WO2011131646A1 (en) 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
WO2013128003A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
KR20160021758A (ko) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
NZ727420A (en) 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
GR20140100479A (el) 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3204408B1 (en) 2014-10-10 2020-05-06 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
CN105753964A (zh) 2014-12-16 2016-07-13 深圳翰宇药业股份有限公司 一种萨摩鲁肽的制备方法及其中间体
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016124687A1 (en) 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
EP3307768A1 (en) 2015-06-12 2018-04-18 Novo Nordisk A/S Selective pyy compounds and uses thereof
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3377521A4 (en) 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
CN108473547A (zh) 2015-10-28 2018-08-31 塔夫茨大学 具有改良的蛋白质分解安定性的新颖多肽，以及制备与使用该新颖多肽的方法
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
KR20190017017A (ko) 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018032521A1 (zh) 2016-08-19 2018-02-22 深圳市健元医药科技有限公司 一种利拉鲁肽的合成方法
CN106478806B (zh) 2016-10-24 2019-08-30 合肥国肽生物科技有限公司 一种索玛鲁肽的固相合成方法
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN106749613B (zh) 2016-12-02 2020-08-18 江苏诺泰澳赛诺生物制药股份有限公司 一种索玛鲁肽的合成方法
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
EP3645031A4 (en) 2017-06-30 2021-03-31 Adepthera LLC PEPTIDIC ANALOGUES
MX2020001434A (es) 2017-08-17 2020-03-20 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos.
MA50474A (fr) 2017-09-25 2020-09-02 Merck Sharp & Dohme Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
WO2019069274A1 (en) 2017-10-04 2019-04-11 Chemical & Biopharmaceutical Laboratories Of Patras S.A. PROCESS FOR THE PREPARATION OF A GLUCAGON-LIKE PEPTIDE
CN108359005A (zh) 2017-11-24 2018-08-03 江苏师范大学 非洲爪蟾glp-1类似物及其用途
TW202415675A (zh) 2017-12-21 2024-04-16 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US11186608B2 (en) 2017-12-21 2021-11-30 Bachem Holding Ag Solid phase synthesis of acylated peptides
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140025A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
SG11202006903WA (en) 2018-01-31 2020-08-28 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MX2020008902A (es) 2018-02-27 2020-12-03 Zp Spv 3 K/S Analogos de compstatina y sus usos medicos.
ES2962666T3 (es) 2018-03-09 2024-03-20 Fresenius Kabi Ipsum S R L Síntesis quimioenzimática de liraglutida, semaglutida y GLP-1
EP4364751A3 (en) 2018-04-05 2024-06-26 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
CA3097812A1 (en) 2018-04-25 2019-10-31 Janssen Pharmaceutica Nv Thioether cyclic peptide amylin receptor modulators
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020023382A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
CN109021092A (zh) 2018-07-23 2018-12-18 安徽省国平药业有限公司 一种索玛鲁肽的合成方法
CA3178366A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
CN108676087B (zh) 2018-07-24 2020-06-30 江苏诺泰澳赛诺生物制药股份有限公司 一种索玛鲁肽的合成方法
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020074583A1 (en) 2018-10-09 2020-04-16 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glp-1 analogues
GB201816639D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
US20220298218A1 (en) 2018-12-03 2022-09-22 Antag Therapeutics Aps Modified GIP Peptide Analogues
EP3872116A4 (en) 2018-12-10 2022-07-27 SK Chemicals Co., Ltd. POLYAMIDE-10 WITH EXCELLENT MECHANICAL AND THERMAL PROPERTIES AND PROCESS FOR ITS PRODUCTION
CN111349155B (zh) 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 一种胰高血糖素类似物及其制备方法和用途
CN109456402A (zh) 2018-12-31 2019-03-12 江苏诺泰澳赛诺生物制药股份有限公司 一种索玛鲁肽的合成方法
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
WO2021034728A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions and particles for payload delivery
PE20221049A1 (es) 2019-08-19 2022-06-30 Lilly Co Eli Metodos para preparar analogos de incretina
CA3148536A1 (en) 2019-08-27 2021-03-04 Anne Pernille Tofteng SHELTON Compstatin analogues and their medical uses
CA3153062A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
CN110642935A (zh) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110627877A (zh) 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
JP2022551282A (ja) 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
WO2021070202A1 (en) 2019-10-09 2021-04-15 Prasad Alaparthi Lakshmi A method for preparing glp-1 analogue by solid-phase peptide synthesis
CN110903355A (zh) 2019-10-31 2020-03-24 成都圣诺生物制药有限公司 一种Tirzepatide的制备方法
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
TW202135811A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 使用整聯蛋白抑制劑組合治療肝臟疾病
MX2022008139A (es) 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
MX2022008130A (es) 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Derivado de insulina.
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN111116731A (zh) 2020-01-09 2020-05-08 山东大学 一种基于可溶性疏水标记载体的液相法制备索马鲁肽的方法
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113423723B (zh) 2020-01-19 2023-06-13 深圳市健元医药科技有限公司 一种索玛鲁肽的制备方法
AR121093A1 (es) 2020-01-23 2022-04-20 Lilly Co Eli Compuestos coagonistas de gip / glp1
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
EP4100417A2 (en) 2020-02-05 2022-12-14 Eli Lilly and Company Resin reactors in series peptide synthesizer
CN111234015B (zh) 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
CN111253475B (zh) 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
JP2023519516A (ja) 2020-03-06 2023-05-11 サノフイ 選択的ｇｉｐ受容体アゴニストとしてのペプチド
CN113493504B (zh) 2020-03-18 2024-02-27 深圳纳福生物医药有限公司 GIP-Exendin-4嵌合肽的分子改构及其二聚体在治疗糖尿病中的应用
CN115315438A (zh) 2020-04-10 2022-11-08 费森尤斯卡比肿瘤学有限公司 索玛鲁肽侧链的改进制备方法
US20230220036A1 (en) 2020-05-05 2023-07-13 Neuland Laboratories Limited Improved process for the preparation of semaglutide
US20230174608A1 (en) 2020-05-09 2023-06-08 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Polypeptide Derivative Having Dual Receptor Agonistic Action and Use Thereof
CN113637064B (zh) 2020-05-11 2023-11-28 深圳市健翔生物制药有限公司 一种索玛鲁肽的合成方法
KR20230017844A (ko) 2020-05-26 2023-02-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 부갑상선기능저하증의 치료를 위한 pth 유사체
TW202144393A (zh) 2020-05-29 2021-12-01 大陸商北京拓界生物醫藥科技有限公司 Ｇｌｐ－１和ｇｉｐ受體雙重激動劑化合物及其應用
US20230241164A1 (en) 2020-06-12 2023-08-03 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
WO2022007809A1 (zh) 2020-07-06 2022-01-13 鸿绪生物医药科技（北京）有限公司 新型多肽制剂及其治疗用途
US20230263896A1 (en) 2020-07-06 2023-08-24 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic use thereof
AU2021309548A1 (en) 2020-07-16 2023-02-23 Zp Spv 3 K/S Inhibitors of complement factor C3 and their medical uses
GB202011604D0 (en) 2020-07-27 2020-09-09 Heptares Therapeutics Ltd GLP-1 receptor antagonists
WO2022026633A1 (en) 2020-07-28 2022-02-03 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN111732650B (zh) 2020-08-04 2020-12-08 苏州金顶生物有限公司 索马鲁肽的连续流固相反应制备
EP4192853A1 (en) 2020-08-07 2023-06-14 Boehringer Ingelheim International GmbH Soluble npy2 receptor agonists
CN111718407A (zh) 2020-08-14 2020-09-29 北京质肽生物医药科技有限公司 一种胰高血糖素样肽-1类似物的纯化方法
CN114075275A (zh) 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效胰岛素类似物
JP2023541798A (ja) 2020-08-19 2023-10-04 サノフイ Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
CN112110981B (zh) 2020-09-23 2021-06-25 深圳深创生物药业有限公司 一种包含长链脂肪二酸侧链的多肽的制备方法
CN115925995A (zh) 2020-09-30 2023-04-07 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
PE20231309A1 (es) 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
AU2021374843A1 (en) 2020-11-09 2023-06-08 Novo Nordisk A/S Compounds and their use in treatment of tachykinin receptor mediated disorders
WO2022115799A1 (en) 2020-11-30 2022-06-02 Rayzebio, Inc. Radiopharmaceutical conjugates targeting guanylyl cyclase c, and compositions and uses thereof
BR112023010891A2 (pt) 2020-12-02 2023-10-17 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Compostos polipeptídicos modificados com lactama
WO2022117044A1 (en) 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
AU2021399076B2 (en) 2020-12-16 2024-07-11 Medimmune Limited Polypeptides and uses thereof
CN116917311A (zh) 2020-12-17 2023-10-20 I2O治疗公司 长效胰高血糖素样多肽-1(glp-1)受体激动剂和其使用方法
TW202227474A (zh) 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ－１及澱粉素受體之共促效劑
TW202317174A (zh) 2020-12-18 2023-05-01 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
KR20230126712A (ko) 2020-12-23 2023-08-30 제지앙 도어 바이오로직스 코., 엘티디. 지속형 글루카곤 유도체
CN114981285B (zh) 2020-12-26 2023-08-29 深圳市健元医药科技有限公司 肽的c端保护片段合成法
CN112661815B (zh) 2020-12-30 2022-12-27 江苏诺泰澳赛诺生物制药股份有限公司 一种Tirzepatide的纯化方法
CN112592387B (zh) 2020-12-31 2023-04-18 江苏诺泰澳赛诺生物制药股份有限公司 一种Tirzepatide的制备方法
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR20230146040A (ko) 2021-02-16 2023-10-18 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 글루카곤 유사 펩타이드-1 수용체 길항물질
US20240100127A1 (en) 2021-02-17 2024-03-28 Eli Lilly And Company Tirzepatide therapeutic methods
WO2022178366A1 (en) 2021-02-21 2022-08-25 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
CN113045641A (zh) 2021-03-19 2021-06-29 合肥科生景肽生物科技有限公司 一种索马鲁肽的制备方法
CN113583106A (zh) 2021-08-03 2021-11-02 中肽生化有限公司 一种索玛鲁肽的制备方法
CN114031680B (zh) 2021-09-01 2024-03-26 浙江湃肽生物有限公司 一种索玛鲁肽钠盐及其制备方法与应用
CN113754753A (zh) 2021-09-30 2021-12-07 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法
CN113880935B (zh) 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法
CN114249810A (zh) 2021-12-09 2022-03-29 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法
CN114949183B (zh) 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法

Also Published As

Publication number Publication date
MX2023008330A (es) 2024-01-18
US20240058415A1 (en) 2024-02-22
AU2022210988B9 (en) 2024-02-22
WO2022159395A1 (en) 2022-07-28
AU2022210988A1 (en) 2023-08-17
JP2023554693A (ja) 2023-12-28
IL304214A (en) 2023-09-01
CN116710462A (zh) 2023-09-05
EP4281464A1 (en) 2023-11-29
AU2022210988B2 (en) 2023-11-16
KR20230125093A (ko) 2023-08-28
US11744873B2 (en) 2023-09-05
US20230105647A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CA3204051A1 (en) Compositions and methods for the treatment of metabolic and liver disorders
US10293053B2 (en) Silanol based therapeutic payloads
RU2489423C2 (ru) Водорастворимые аналоги сс-1065 и их конъюгаты
ES2682043T3 (es) Ibrutinib deuterado
US20190290771A1 (en) Silicon based drug conjugates and methods of using same
TW201117826A (en) Fatty acid niacin conjugates and their uses
US20210347727A1 (en) Calpain modulators and therapeutic uses thereof
IL311411A (en) Preparations and methods for the treatment of metabolic and liver disorders
ES2894324T3 (es) Derivados del dextrorfano con actividad nerviosa central suprimida
US20210253642A1 (en) Calpain modulators and therapeutic uses thereof background
WO2016180334A1 (zh) 双位点不可逆布鲁顿酪氨酸激酶抑制剂、组合物及其应用
US20240239843A1 (en) Compositions and methods for the treatment of metabolic and liver disorders
WO2024020372A1 (en) Compositions and methods for the treatment of metabolic and liver disorders
WO2024020388A1 (en) Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2023141044A1 (en) Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
ES2274268T3 (es) Compuestos y composiciones para el tratamiento de la diabetes y trastornos relacionados con la diabetes.
US20220348601A1 (en) Ruthenium arene schiff-base complexes and uses thereof
US20230133504A1 (en) Method of treating graft-versus-host disease
CZ9904585A3 (cs) Způsob ošetřování odolnosti proti inzulínu sekretagogy růstového hormonu

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230630

EEER Examination request

Effective date: 20230630

EEER Examination request

Effective date: 20230630

EEER Examination request

Effective date: 20230630

EEER Examination request

Effective date: 20230630